Skip to main content

2 Result(s)

within Sarah Matthews Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. No Access

    Article

    A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

    Purpose: The epidermal growth factor receptor (EGFR) appears relevant in the pathogenesis and progression of colorectal cancer. After completing a phase I pharmacodynamic trial of ZD1839, we undertook a dose expa...

    Mary J. MacKenzie, Holger W. Hirte, Goss Glenwood, Maroun Jean… in Investigational New Drugs (2005)

  2. No Access

    Article

    Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98)

    Background: The primary objective of this Phase I study was to determine the maximum tolerated dose (MTD) and recommended phase II dose for Tomudex and doxorubicin when given in combination to patients w...

    Georg A. Bjarnason, Danielle Charpentier, Ralph Wong… in Investigational New Drugs (2005)